Silodosin
Brand names: Rapaflo, Silodosin
At a glance
- Medicare prescriptions, 2024
- 209,267
- Medicare drug cost
- $17.4M
- Average cost per prescription
- $82.97
- Clinicians who prescribed it
- 6,146
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Silodosin capsule, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Urology 61.6%
- Nurse Practitioners 10.2%
- Physician Assistants 10.0%
- Internal Medicine 8.6%
- Family Medicine 5.3%
- Geriatric Medicine 1.0%
- Nephrology (Kidney) 0.5%
- Cardiology 0.4%
- Radiation Oncology 0.4%
- General Practice 0.3%
- Hospitalist 0.3%
- Infectious Disease 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 28% from 2019 to 2024.
Biggest change by state since 2019
- Ohio +54%
- North Carolina +41%
- Virginia +33%
- Texas +26%
- Florida +26%
- South Carolina (smallest change) −2%
- Illinois (smallest change) +9%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 8 mg | white capsule, 19 mm | I88 |
Novadoz Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 4 mg | white capsule, 15 mm | S 4MG |
| 8 mg | white capsule, 19 mm | S 8MG |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 4 mg | white capsule, 16 mm | SIL 4MG |
Physicians Total Care, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 8 mg | white capsule, 19 mm | WATSON 152 8 MG |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Feb 2025 · Avkare · Class II
Subpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 105%)
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.